Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126286761 | 12628676 | 1 | I | 20150917 | 0 | 20160805 | 20160805 | DIR | 40.00 | YR | F | N | 135.00000 | LBS | 20160804 | N | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126286761 | 12628676 | 1 | PS | SERTRALINE | SERTRALINE HYDROCHLORIDE | 1 | Oral | 1 TABLET AT BEDTIME | N | Y | 0 | 1 | DF | COATED TABLET | HS | ||||
| 126286761 | 12628676 | 3 | C | GABAPENTIN. | GABAPENTIN | 1 | 0 | ||||||||||||
| 126286761 | 12628676 | 5 | C | PYRIDOSTIGMINE | PYRIDOSTIGMINE | 1 | 0 | ||||||||||||
| 126286761 | 12628676 | 7 | C | CAFFEINE. | CAFFEINE | 1 | 0 | ||||||||||||
| 126286761 | 12628676 | 9 | C | RANITIDINE. | RANITIDINE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126286761 | 12628676 | 1 | Depression |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126286761 | 12628676 | Asthenia | |
| 126286761 | 12628676 | Dysstasia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126286761 | 12628676 | 1 | 20150917 | 20160229 | 0 |